Analysis

Patentees Get Boost With China's Version Of Hatch-Waxman

Law360 (June 3, 2021, 10:28 PM EDT) -- A new Chinese litigation system for drug patents that is modeled on the U.S. Hatch-Waxman Act could be a boon for branded drugmakers by resolving infringement disputes before generic products launch, but the industry will be monitoring whether it works as intended.

China's new framework, which took effect this week, was created by a law enacted in October and will mean that owners of drug patents can file infringement suits over planned generic drugs without having to wait until those competing products are on sale.

Akin to Hatch-Waxman, the so-called patent linkage system provides a mechanism for branded drug companies to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!